Siemens Backs Startup's AI-Powered MRI, Signals Future of Diagnostics

ORLANDO, FL – March 20, 2026 – In a move signaling strong interest in the next wave of diagnostic innovation, medtech giant Siemens Healthineers has issued a Letter of Support to Imaginostics, Inc., a pre-FDA stage startup. The letter formalizes ongoing exploratory discussions between the two companies, focusing on a potential collaboration in the field of quantitative Magnetic Resonance Imaging (MRI) and advanced imaging biomarkers.

This development centers on the potential integration of Imaginostics' envisioned ImagiView™ and ImagiSight™ software offerings with Siemens Healthineers' widely used MAGNETOM MRI systems. While not a definitive partnership, the endorsement from an industry titan provides significant validation for Imaginostics' mission to transform medical imaging from a subjective art into an objective science.

"This Letter of Support marks an important milestone for Imaginostics, and we look forward to continuing the technical and commercial dialogue with Siemens Healthineers," said Valerie Gharagouzloo, Co-Founder and CEO of Imaginostics, in a statement. The dialogue aims to chart a course for a technology that promises to reshape preventative medicine.

The Validation Effect in MedTech

In the high-stakes, capital-intensive world of medical technology, a 'Letter of Support' from a market leader like Siemens Healthineers is more than just a document; it's a powerful currency. For a nascent company like Imaginostics, which has yet to bring a product to market, this endorsement serves as a critical de-risking event for investors and a beacon of credibility for the wider healthcare industry.

Industry analysts note that such letters are often a precursor to deeper, more formal relationships, such as joint development agreements, strategic investments, or distribution deals. They signify that after initial discussions, the larger corporation sees genuine potential and strategic alignment. The process typically involves extensive due diligence, where the startup's technology, regulatory strategy, and commercial viability are rigorously assessed.

The announcement makes clear that any future commercial activity remains subject to further discussions and definitive agreements. However, the initiation of this formal dialogue suggests that Imaginostics' technology has successfully captured the attention of a company that is itself a major force in the evolution of diagnostic imaging. This move is indicative of a broader trend where established players partner with agile startups to accelerate innovation and maintain a competitive edge.

Beyond the Scan: The Promise of 'Vascular Intelligence'

At the heart of the discussion is the transformative potential of quantitative MRI (qMRI). For decades, radiologists have interpreted MRI scans based on visual assessment of anatomical structures—a process that, while highly skilled, carries an inherent level of subjectivity. The goal of qMRI is to change that paradigm.

"Quantitative MRI and imaging biomarkers have the potential to make imaging more objective, reproducible, and clinically actionable," noted Dr. Codi Gharagouzloo, Imaginostics' Scientific Founder and CSO. This means moving beyond qualitative descriptions to generating hard, numerical data directly from the scans.

Imaginostics is developing what it calls "vascular intelligence." The company aims to use its proprietary qMRI technology to create AI-powered, data-driven "digital twin insights" of a patient's vascular system. The technology is designed to detect subtle, early-stage changes in tissue and blood vessels that are invisible to the naked eye on a conventional scan. This could be a game-changer for complex, slow-progressing conditions like cardiovascular disease—the leading cause of death globally, according to the World Health Organization.

By identifying these early warning signs, the technology could enable a fundamental shift from reactive to preventative healthcare. Clinicians could gain a more personalized understanding of a patient's risk, allowing for tailored interventions—from lifestyle changes to targeted therapies—long before a catastrophic event like a heart attack or stroke occurs.

A Strategic Fit in a Competitive Landscape

The potential collaboration is not a one-way street. It aligns perfectly with Siemens Healthineers' own strategic push into precision medicine, artificial intelligence, and quantitative imaging. The company has already invested heavily in integrating AI into its platforms, with tools like the AI-Rad Companion family designed to automate routine tasks and extract quantitative data from scans. Furthermore, Siemens has demonstrated an open-minded approach to innovation, previously partnering with companies like HeartVista to integrate third-party cardiac imaging AI into its MRI machines.

By exploring a collaboration with Imaginostics, Siemens Healthineers is positioning itself to potentially enhance its MAGNETOM systems with a first-of-its-kind capability in vascular health diagnostics. In a competitive market where major players like GE Healthcare and Philips are also heavily investing in AI and quantitative analysis, unique and clinically impactful applications are a key differentiator.

Imaginostics' focus on vascular health is particularly timely. The ability to provide objective, non-invasive biomarkers for cardiovascular and cerebrovascular health addresses a significant unmet clinical need, tapping into the massive and growing markets for preventative care and precision diagnostics.

The Road Ahead: Navigating a Complex Path to Market

Despite the promising outlook, the path from a Letter of Support to a widely available clinical product is long and fraught with challenges. As a pre-FDA company, Imaginostics must navigate the complex regulatory landscape for Software as a Medical Device (SaMD).

This will involve extensive clinical validation to prove not only that its technology is safe and accurate but that it provides tangible clinical utility—meaning its use must lead to better patient outcomes. The company will need to generate a robust body of evidence to convince regulators, clinicians, and healthcare payers of its value. This process can take years and requires significant capital investment.

Beyond regulatory hurdles, technical integration is a key milestone. Ensuring that ImagiView™ and ImagiSight™ can work seamlessly and securely within the diverse ecosystem of Siemens' MAGNETOM MRI systems in a real-world clinical workflow is a critical step. The success of this technical evaluation will be a major determinant in whether the exploratory talks mature into a definitive partnership.

For now, the dialogue represents a convergence of a startup's bold vision and an industry leader's strategic foresight. It marks a significant step toward a future where a simple MRI scan could provide a deep, quantitative look into our vascular health, empowering a new era of preventative medicine.